Photo from wikipedia
Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). We assess the effect of tofacitinib + conventional synthetic disease‐modifying anti rheumatic drugs (csDMARDs) on patient‐reported… Click to show full abstract
Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). We assess the effect of tofacitinib + conventional synthetic disease‐modifying anti rheumatic drugs (csDMARDs) on patient‐reported outcomes in Chinese patients with RA and inadequate response to DMARDs.
Keywords:
tofacitinib conventional;
conventional synthetic;
disease modifying;
synthetic disease;
rheumatoid arthritis;
patient reported
Journal Title: International Journal of Rheumatic Diseases
Year Published: 2018
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: International Journal of Rheumatic Diseases
Year Published: 2018
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!